Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to 23.7%.

  • Cumberland Pharmaceuticals' EBITDA Margin fell 50500.0% to 23.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.9%, marking a year-over-year increase of 213700.0%. This contributed to the annual value of 16.99% for FY2024, which is 71700.0% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported EBITDA Margin of 23.7% as of Q3 2025, which was down 50500.0% from 6.9% recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' EBITDA Margin peaked at 11.03% during Q1 2025, and registered a low of 66.07% during Q4 2023.
  • In the last 5 years, Cumberland Pharmaceuticals' EBITDA Margin had a median value of 17.65% in 2024 and averaged 17.73%.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' EBITDA Margin plummeted by -411000bps in 2023 and then surged by 484100bps in 2024.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' EBITDA Margin stood at 52.33% in 2021, then soared by 52bps to 24.97% in 2022, then plummeted by -165bps to 66.07% in 2023, then soared by 73bps to 17.65% in 2024, then crashed by -34bps to 23.7% in 2025.
  • Its EBITDA Margin was 23.7% in Q3 2025, compared to 6.9% in Q2 2025 and 11.03% in Q1 2025.